Sex influences the effects of APOE genotype and Alzheimer's diagnosis on neuropathology and memory

Paula Duarte-Guterman[1][#], Arianne Y. Albert[2], Cindy K. Barha[3], Liisa A.M. Galea[1], on behalf of the Alzheimer's Disease Neuroimaging Initiative[δ]

[1.] Djavad Mowafaghian Centre for Brain Health and Department of Psychology, University of British Columbia, Vancouver, BC, Canada

[2.] Women's Health Research Institute of British Columbia, Vancouver, BC, Canada

[3.] Djavad Mowafaghian Centre for Brain Health and Department of Physical Therapy, University of British Columbia, Vancouver, BC, Canada

Address all correspondence and requests for reprints to:
L. A. M. Galea, PhD
Djavad Mowafaghian Centre for Brain Health
2215 Wesbrook Mall
Vancouver, British Columbia
V6T 1Z3, Canada
E-mail: liisa.galea@ubc.ca

[#] Present Address: Department of Psychology, Brock University, St. Catharines, ON, Canada

[δ] Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

Declarations of interest: none

Keywords: mild cognitive impairment; tau, amyloid beta; hippocampus; executive function; gender.

36 **Highlights**

37 • CSF tau pathology was elevated in female APOEε4 carriers compared to male carriers

38 • CSF amyloid beta levels were reduced in male APOEε4 carriers relative to female carriers

39 • Severity of diagnosis decreased memory scores to a greater extent in females

Abstract

Alzheimer's disease (AD) is characterised by severe cognitive decline and pathological changes in the brain (brain atrophy, hyperphosphorylation of tau, and deposition of toxic amyloid-beta protein). Females have greater neuropathology (AD biomarkers and brain atrophy rates) and cognitive decline than males, however these effects can depend on diagnosis (amnestic mild cognitive impairment (aMCI) or AD) and APOE genotype (presence of ε4 alleles). Using the ADNI database (N=630 females, N=830 males), we analysed the effect of sex, APOE genotype (non-carriers or carriers of APOEε4 alleles), and diagnosis (cognitively normal (CN), early aMCI (EMCI), late aMCI (LMCI), AD) on cognition (memory and executive function), hippocampal volume, and AD biomarkers (CSF levels of amyloid beta, tau and ptau). More males were diagnosed with aMCI but there was no sex difference in those diagnosed with AD, suggesting the progression from CN, aMCI to AD is sex-specific. Regardless of APOE genotype, memory scores were higher in CN, EMCI, and LMCI females compared to males but this sex difference was absent in AD, which may suggest a delay in the onset of cognitive decline or diagnosis and/or a faster trajectory of cognitive decline in females. We found that, regardless of diagnosis, CSF tau-pathology was disproportionately elevated in female carriers of APOEε4 alleles compared to males. In contrast, male carriers of APOEε4 alleles had reduced levels of CSF amyloid beta compared to females, irrespective of diagnosis. We also detected sex differences in hippocampal volume but the direction was dependent on the method of correction. Altogether results suggest that across diagnosis females show greater memory decline compared to males and APOE genotype affects AD neuropathology differently in males and females which may influence sex differences in incidence and progression of aMCI and AD.

1. Introduction

Alzheimer's disease (AD) is characterized by severe cognitive decline and neuropathological markers such as brain atrophy, hyperphosphorylation of tau, and deposition of toxic amyloid-beta (Aβ) protein in the brain (Alzheimer's Association, 2017). The hippocampus is one of the first brain areas to show atrophy with AD (Jack et al., 2000; Kidron et al., 1997) and hippocampal atrophy correlates with cognitive decline (Petersen et al., 2000) and AD pathology (neurofibrillary tangles; Jack et al., 2002). Possession of one or two APOEε4 alleles, the strongest genetic risk factor for sporadic AD, and female sex are important non-modifiable risk factors for AD (Riedel et al., 2016). Studies indicate that females with AD show greater signs of neuropathology (tau levels), rates of brain atrophy, including in the hippocampus, and cognitive decline than males, which may be exacerbated by APOE genotype (e.g., Ardekani et al., 2016; Buckley et al., 2018; Cavedo et al., 2018; Hohman et al., 2018). One allele of APOEε4 increases the risk of AD in females relative to males between 65 and 75 years, indicating that the APOE genotype affects males and females differently (Neu et al., 2017).

Previous studies have examined the interaction of APOE genotype and sex on AD biomarkers (tau and Aβ), hippocampal atrophy, and cognitive function, but findings are not consistent (Altmann et al., 2014; Buckley et al., 2018; Damoiseaux et al., 2012; Holland et al., 2013; Liu et al., 2019; Sampedro et al., 2015; Sohn et al., 2018; Wang et al., 2019), likely due to the diagnosis groups included and whether studies use longitudinal or baseline comparisons. Using the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, previous studies found a stronger association between APOEε4 and CSF tau levels in females compared to males at baseline in cognitively normal (CN; Damoiseaux et al., 2012; but see Sampedro et al., 2015) and amnestic mild cognitive impairment (aMCI) individuals (Altmann et al., 2014; Liu et al., 2019) but no studies to our knowledge have investigated the interactions between sex and APOE

genotype in individuals with AD. Females with APOEε4 alleles have steeper hippocampal

volume reductions with age in CN individuals (Holland et al., 2013) and show greater cognitive

decline in aMCI individuals (Sohn et al., 2018; Wang et al., 2019) compared to males but these

findings are not consistent (Buckley et al., 2018). Although there are several ADNI studies that

have examined sex by APOE genotype interactions on AD biomarkers, most of these studies

included only one diagnosis group, with either only CN (Buckley et al., 2019a, 2018) or aMCI

groups (Liu et al., 2019; Sohn et al., 2018) or analysed the groups (CN, aMCI, AD) separately

(Sundermann et al., 2018). It is important to include all three diagnosis groups CN, aMCI and

AD to understand how sex may interact with APOE genotype to influence AD biomarkers across

diagnosis. In order to improve diagnosis and treatment, it is important to understand why females

are at a higher lifetime risk and have a higher burden of the disease than males and whether this

is across diagnosis and APOE genotype for a number of AD biomarkers.

Sex differences in memory depend on memory domain, females perform better in

episodic memory tasks related to verbal memory, whereas males perform better in visuospatial-

related tasks (meta-analysis by Asperholm et al., 2019). Furthermore, there are sex differences in

some forms of executive function depending on the type of executive function being examined,

with a male advantage for working memory and a female advantage on response inhibition in

cognitively healthy adults (Gaillard et al., 2020). In tasks that involve the integrity of the

hippocampus, males typically outperform females in both humans and rodents (Yagi and Galea,

2019). In addition, while sex differences in hippocampal volume have been detected, with

females having a smaller volume compared to males, this depends on whether the data are

corrected for individual differences in brain volume and the method of correction employed

(meta-analysis by Tan et al., 2016). Understanding basic sex differences in hippocampal function

and structure is important to determine how they can contribute to sex differences in

vulnerability and progression of neurodegenerative diseases in which the integrity of the

hippocampus is affected such as in AD.

The objective of this study was to examine sex differences in AD biomarkers (CSF Aβ,

tau, and phosphorylated tau), volume of the hippocampus (using two correction factors),

memory, and executive function, and how these may be affected by APOE genotype (non-

carriers or carriers of APOEε4 alleles) and diagnosis status (CN, aMCI, AD). We hypothesized

that females will be more affected by APOE genotype and diagnosis and this will be reflected in

greater AD pathology, smaller hippocampus volume, and lower cognitive scores than males with

AD and this is exacerbated in female carriers of APOEε4 alleles.

2. Materials and methods

2.1 ADNI database

Data used in the preparation of this article were obtained from the Alzheimer's Disease

Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in

2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner,

MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging

(MRI), positron emission tomography (PET), other biological markers, and clinical and

neuropsychological assessment can be combined to measure the progression of mild cognitive

impairment (MCI) and early Alzheimer's disease (AD). For up-to-date information, see

www.adni-info.org. Data used in this article were downloaded on or before Jan 16, 2019.

Inclusion and exclusion criteria are detailed online

(http://adni.loni.usc.edu/methods/documents/). Briefly, CN participants had normal memory

function (measured by education-adjusted scores on the Wechsler Memory Scale Logical

Memory II) and a Clinical Dementia Rating (CDR) of 0. Amnestic late MCI (LMCI) participants

had objective memory loss (from Wechsler Memory Scale Logical Memory II scores), a CDR of

0.5, preserved daily activities, and absence of dementia. Early MCI (EMCI) participants had a

milder episodic memory impairment compared to LMCI (Wechsler Memory Scale Logical

Memory II scores ~0.5 and 1.5 SD below the mean of CN participants). All AD participants met

NINCDS/ADRDA Alzheimer's Criteria and a CDR of 0.5 or 1.0.

2.2 CSF biomarkers, hippocampal volume, memory, and executive function

We included all participants who had the following baseline data: diagnosis in the ADNI

database, cerebrospinal fluid (CSF) levels for Aβ, tau and phosphorylated tau (ptau), had a brain

MRI scan, and underwent a battery of neuropsychological tests (total n = 1,460, n= 630 females,

n=830 males; Table 1). Data included in our analyses were: demographics (age, years of

education, and ethnicity), baseline diagnosis (cognitively normal, CN; EMCI; LMCI; or AD),

number of APOE ε4 alleles (0, 1 or 2), CSF Aβ (pg/ml), CSF tau (pg/ml), and CSF p-tau

(pg/ml), hippocampal volume (mm^3), ADNI executive function z-scores, and ADNI memory z-

scores (using data from the ADNI neuropsychological battery and validated in Crane et al., 2012;

Gibbons et al., 2012). The executive function score included WAIS-R Digit Symbol Substitution,

Digit Span Backwards, Trails A and B, Category Fluency, and Clock Drawing (Gibbons et al.,

2012). The composite memory score included Rey Auditory Verbal Learning Test, AD

Assessment Schedule - Cognition, Mini-Mental State Examination, and Logical Memory data

(Crane et al., 2012). Sex differences in hippocampal volume are influenced by controlling factors

such as intracranial volume (Lotze et al., 2019; Tan et al., 2016). In the present study, we

corrected hippocampus volume using two different methods. The first method (regression

method) used the method in Mormino et al. (2014) and Jack et al. (2012) using the residuals of

the linear regression between hippocampal volume and total intracranial volume. We also

compared another widely used volume correction method (Sohn et al., 2018; Sundermann et al.,

2018; meta-analysis by Tan et al., 2016) by dividing hippocampal volume with intracranial

volume to directly compare the different correction methods.

2.3 Statistical Methods

We compared all available data for each study variable between the sexes using the

Wilcoxon rank sum test for continuous variables and Fisher's exact test for categorical variables.

We used general linear models to determine the relationships between sex, APOE genotype

(non-carriers or carriers of APOEε4 alleles), and diagnosis status (CN, EMCI, LMCI, and AD)

as predictor variables, and AD biomarkers, corrected hippocampal volume, and cognitive ability,

as dependent variables. All models included age and years of education as a covariate. All

models initially included the three-way interaction between sex, APOE genotype, and diagnosis;

if this interaction was not significant, it was removed from the model to estimate the two way

interactions (sex and APOE genotype, sex and diagnosis, APOE genotype and diagnosis). If no

two-way interactions were significant, these were removed from the model to estimate the main

effects of sex, APOE genotype, and diagnosis. Significance was based on the likelihood ratio

test, and all p-values were corrected for multiple testing using the Benjamini-Hochberg false

discovery rate method with the family-wise error rate set to 0.05 (Benjamini and Hochberg,

1995). In total, seven p-values per dependent variable were included in each set of models

(interaction terms and main effects of sex, APOE, and diagnosis) resulting in 49 p-values

corrected (seven dependent variables; Tables 1 and 2). Significant interaction terms were

followed up using pairwise simple-effects tests with Benjamini-Hochberg p-value correction. We

calculated Pearson's correlation coefficients between CSF levels of tau and Aβ by sex and APOE

genotype separately. We report significance differences (adjusted $p \leq 0.05$) and trends (adjusted

$p \leq 0.08$). All regression analyses were carried out in R v3.5.1 (R Core Team, 2018).

3. Results

3.1 Demographic information

Table 1 gives a summary of the variables in the data set (N=1460). Overall, females were

significantly younger and had fewer years of education than males (p's<0.0001) and hence age

and education were used as covariates in all analyses. There were more white males than white

females in our sample and more non-white females compared to non-white males (p<0.05). In

terms of APOE genotype, there were no sex differences in distribution of APOE genotype with

40% females and 38.8% males possessing one allele of APOEε4, and 11% females and 12% of

males possessing two alleles of APOEε4. The proportion of participants in each of the diagnosis

categories was significantly different for females and males (p<0.05). More females were

cognitively normal than males (26.7% compared to 20.8%, unadjusted p=0.01) but there were no

sex differences in baseline diagnosis of AD (females: 23.7% compared to males: 21.7%,

unadjusted p=0.41). However, there were more males with a diagnosis of LMCI (39.5% versus

32.5%, unadjusted p=0.007) but not EMCI (18.0% versus 17.1%, unadjusted p=0.74) compared

to females.

We tested whether sex, APOE genotype (non-carriers or carriers of APOEε4 alleles), and

diagnosis status (CN, EMCI, LMCI, and AD) influenced cognitive ability, corrected

hippocampal volume, and CSF biomarkers of AD in one model. However, we did not find

significant interactions between these three factors in any of the models (i.e. none of the three-

way interactions were significant). We did find significant two-way interactions between sex and

APOE genotype, sex and diagnosis, and APOE genotype and diagnosis (Table 2) on these

dependent variables, which are discussed in turn below.

3.2. Sex and APOE genotype were associated with changes in CSF AD biomarkers

We found significant interactions between sex and APOE genotype for CSF tau, and p-

tau (p=0.005 and 0.006, respectively), and a trend for CSF Aβ (p=0.051; Table 2). Tau and p-tau

levels were significantly higher in female carriers of APOEε4 alleles compared to male carriers

(all p's<0.0001; Fig. 1 A and B) but no sex differences were detected in non-carriers of APOEε4

alleles (p>0.3). Although CSF tau and p-tau levels were also higher in males with APOEε4

genotype, the difference in levels between carriers and non-carriers was more pronounced in

females (standardized regression coefficients for tau and ptau: 0.46 and 0.49 in females and 0.19

and 0.24 in males). For CSF Aβ, female APOEε4 carriers had higher levels compared to males

carriers (p=0.04) but there were no sex differences in non-carriers (p=0.6; Fig. 1 C). Levels of

Aβ were lower in both sexes in carriers of APOEε4 alleles but the difference between carriers

and non-carriers was more pronounced in males than in females, irrespective of diagnosis

(standardized regression coefficients for Aβ: -0.58 in females and -0.71 in males). There were no

significant sex by diagnosis interactions for AD biomarkers (Table 2).

We next investigated the relationship, using correlations, between CSF tau and Aβ levels

in males and females and by APOE genotype (Table 3). We found significant negative

correlations between CSF levels of tau and Aβ in male and female non-carriers of APOEε4

alleles (r=-0.262, p<0.0001; r=-0. 195, p=0.008, respectively). However, in carriers of APOEε4

alleles, a significant negative correlation was found only in females (r=-0.219, p=0.001) but not

in males (r= -0.046, p=0.44).

3.3. Sex and diagnosis were associated with changes in memory scores

We found a significant interaction between sex and diagnosis for ADNI memory z-scores

(p=0.048; Table 2). Females had significantly higher memory z-scores than males in the CN,

EMCI, and LMCI groups (p<0.001, p<0.001, p<0.01, respectively) while no sex differences

were detected in AD (p=0.1). Thus, severity of diagnosis decreased memory scores to a greater

extent in females, such that there was no longer a sex differences in memory scores in

individuals with AD (Fig. 2). CSF tau and Aβ were each significantly correlated with memory z-

scores in both sexes, regardless of genotype (Table 3). There were no significant sex by APOE

genotype interactions for memory scores (Table 2).

3.4. Diagnosis and APOE are associated with changes in memory, hippocampal volume, and

tau-pathology

Two-way interactions between diagnosis and APOE genotype were detected for memory

z-scores (p=0.006), hippocampal volume (the two correction methods; both p's<0.001), and CSF

tau (p=0.014) and ptau levels (p=0.029) but not for executive function scores or CSF Aβ levels.

As expected, increasing severity of diagnosis decreases memory z-scores in carriers and non-

carriers of APOEε4 alleles (p's<0.001). However, carrying APOEε4 alleles decreased memory

scores in the LCMI group (p<0.0001), but not in the CN, EMCI, and AD groups (all p's>0.2),

compared to non-carriers.

For both methods of hippocampal volume calculation, we found that, irrespective of sex,

carriers of APOEε4 alleles had a smaller volume compared to non-carriers in LMCI and AD

individuals (regression method: $p < 0.0001$ and $p = 0.0004$, respectively; ratio method: $p = 0.0001$

and $p = 0.001$, respectively). There were no significant differences in hippocampal volume

between carriers and non-carriers of APOEε4 alleles in the EMCI and CN groups (p's > 0.5). In

non-carriers, severity of diagnosis was associated with a smaller hippocampal volume, regardless

of method of correction (AD$<$ LMCI$<$ EMCI$<$ CN; p's<0.01). In carriers of APOEε4 alleles,

EMCI diagnosis did not significantly affect hippocampal volume compared to CN individuals

with both methods of correction (p's>0.7) while there was a reduction in hippocampal volume in

AD and LMCI (AD$<$LMCI$<$CN; p's<0.0001). There were no significant sex by diagnosis or sex

by APOE genotype interactions for hippocampal volume (Table 2).

CSF tau and ptau levels increased with the severity of diagnosis but this was affected by

APOE genotype ($p = 0.014$ and $p = 0.029$, respectively). Carrying APOEε4 alleles resulted in

higher levels of CSF tau and ptau in EMCI and LMCI (all p's<0.0001), but not in CN or AD,

individuals (p's>0.17). Regardless of sex, the difference in CSF tau and ptau levels between non-

carriers and carriers of APOEε4 alleles was reduced in individuals with AD compared to EMCI

and LMCI diagnoses.

3.5. Sex is associated with hippocampal volume

Males had a larger hippocampus volume by the regression method, but a smaller

proportion of the brain was devoted to hippocampus (ratio method) when compared to females

(main effect of sex, $p = 0.005$ and $p < 0.0001$, respectively; Table 2). Sex differences in

hippocampal volume were observed regardless of diagnosis or APOE genotype.

3.6. Diagnosis is associated with Aβ and executive function

Irrespective of sex and APOE genotype, increasing severity of diagnosis was associated with lower CSF Aβ levels in LMCI and AD compared to CN individuals (p<0.0001). Aβ levels were similar in CN and EMCI individuals (p=0.1). Increasing severity of diagnosis was associated with lower executive function z-scores (p<0.0001), irrespective of sex and APOE genotype.

4. Discussion

In the present study, we found that APOE genotype affects AD neuropathology differently in males and females. CSF tau pathology was disproportionately elevated in female carriers of APOEε4 alleles, whereas CSF Aβ was disproportionately reduced in male carriers of APOEε4 alleles. These findings suggest that APOE genotype leads to greater AD neuropathology in both sexes that depends on the pathology biomarker, with females more likely to show higher CSF tau levels and males to present with lower CSF Aβ levels (suggesting a higher Aβ deposition). Females displayed higher memory scores than males in CN, EMCI, and LMCI groups but not in AD, which may contribute to delayed diagnosis in females (Sundermann et al., 2017) and/or to the more severe decline in memory across diagnosis in females compared to males (Buckley et al., 2018; Irvine et al., 2012; Wang et al., 2019). Interestingly, depending on the correction method, females had either smaller or larger hippocampus volume compared to males, regardless of APOE genotype or diagnosis. As expected, increasing severity of diagnosis reduced executive function and CSF Aβ, irrespective of sex and APOE genotype, and APOE genotype affected memory, hippocampal volume, and tau-pathology depending on diagnosis.

Previous work has demonstrated sex differences in rates of AD and symptoms of AD (reviewed

in Ferretti et al., 2018; Nebel et al., 2018). Our current study suggests that AD biomarkers (CSF

tau and Aβ) are expressed differently between the sexes with APOE genotype, suggesting

different AD pathology pathways between females and males carriers of APOEε4 alleles. These

data may provide clues to better understand the sex differences in AD lifetime risk and

progression.

4.1 APOE genotype affects tau and Aβ pathology differently between the sexes

We found that levels of tau and p-tau were disproportionately elevated with APOEε4

allele expression in females compared to males. Previous ADNI studies have found a significant

interaction between sex and APOE genotype on levels of CSF tau in CN (Damoiseaux et al.,

2012; but see Sampedro et al., 2015; Buckley et al., 2019a; Altmann et al., 2014) and aMCI

participants (Altmann et al., 2014). A recent meta-analysis found a stronger association between

APOEε4 and tau levels in CN females compared to males using ADNI and other datasets

(Hohman et al., 2018). Our data extends these data by adding that the interaction between sex

and APOE genotype on CSF tau and ptau is seen regardless of diagnosis (in CN, EMCI, LMCI

and AD individuals). Previous studies indicate that females with at least one APOEε4 allele are

at a greater risk for developing AD earlier than are males with this allele (Altmann et al., 2014;

Neu et al., 2017), and sex differences in tau and p-tau may be one underlying mechanism by

which this occurs but further replication with additional and larger populations are needed.

In contrast to tau pathology, CSF Aβ levels were disproportionately reduced in male

APOEε4 carriers compared to females, suggesting a greater Aβ deposition in male carriers of

APOEε4 alleles, regardless of diagnosis. To date, studies have not been consistent regarding sex

differences in CSF Aβ levels or Aβ deposition based on APOE genotype. For example,

somewhat consistent with our findings some studies have found that male APOEε4 carriers have

lower CSF Aβ levels in CN individuals (but not in aMCI individuals; Altman et al., 2014), and

that males, regardless of APOE status, have higher Aβ deposition (using PET) than females in

certain brain regions (i.e., cingulate cortex; Cavedo et al., 2018). However, other studies in

cognitively healthy individuals find no sex differences in Aβ deposition (Jack et al., 2015) or that

females have higher levels of Aβ deposition (Sundermann et al., 2018), regardless of APOE

genotype. Differences between studies may be due to differences between CSF and PET Aβ

levels and types of analysis. Levels of CSF tau are hypothesized to increase after CSF Aβ

declines and Aβ aggregates and deposits in the brain (Blennow et al., 2015). The association

between tau and Aβ is also well characterized, i.e., increasing tau PET levels are associated with

increasing Aβ PET deposition (e.g., Maass et al., 2017). Based on this, we would have expected

lower CSF Aβ to be associated with higher CSF tau and ptau, which is precisely what we found

in females, regardless of APOE genotype, but only in male non-carriers of APOEε4 alleles.

Previous work is consistent with this finding as higher levels of tau PET were more strongly

associated with higher Aβ burden in the entorhinal cortex in females compared to males

(Buckley et al., 2019b). Taken together, this suggests that the weaker relationship between tau

and Aβ in males is due to APOE genotype. However, CSF tau and Aβ were similarly correlated

with memory scores in both sexes and APOE genotype. It is possible that depending on APOE

genotype, the neurodegeneration pathway (tau or Aβ) or timeline of pathology is different

between the sexes, but whichever pathway is present, it is correlated with lower memory scores.

4.2 AD diagnosis decreased memory scores to a greater extent in females

As expected, we found that the presence of APOEε4 alleles and AD diagnosis were

associated with reduced memory and executive function scores consistent with past literature

(Buckner, 2004; Ewers et al., 2012; Petersen et al., 2000). However, memory scores in females

were more affected with diagnosis such that the female memory advantage was reduced with

AD, and this is in line with longitudinal analyses showing females decline faster (although this

may depend on APOE genotype and Aβ burden; Holland et al., 2013; Buckley et al., 2018).

Executive function on the other hand was similarly reduced in females and males with diagnosis.

Previous studies found that females have better verbal memory compared to males across

diagnoses (CN, Jack et al., 2015; aMCI and AD, Sundermann et al., 2018, 2016). Here, we used

the ADNI memory score developed by Crane et al. (2012) to detect abnormal memory including

language, attention, and logical memory so it is possible that verbal memory may be driving the

sex difference favouring females in the present study. In contrast, Buckley et al. (2018) found no

sex differences using a composite cognitive score that includes memory and executive function

(Preclinical Alzheimer's Cognitive Composite score with semantic processing, PACC5) using

ADNI and two other cohorts. Altogether, we found that in females CSF tau pathology was

increased with APOE genotype and that in CN, EMCI and LMCI females (regardless of APOE

genotype) memory and executive function scores were higher compared to males suggesting

females have a reserve against brain pathology that delays either the onset of cognitive decline or

diagnosis (Sundermann et al., 2017). However, once cognitive decline begins, sex differences in

memory scores are reduced (current study) and females show higher rates of declines compared

to males (Buckley et al., 2018; Holland et al., 2013; Hua et al., 2010) perhaps because the

underlying tau pathology is elevated in females.

Females have a higher lifetime risk of AD than males and show greater cognitive decline

with AD than males (reviewed by Ferretti et al., 2018; Nebel et al., 2018). The disproportionate

effect in females compared to males of (1) APOEε4 genotype on tau-related pathology and (2)

AD diagnosis on memory scores supports the idea that females have a higher burden of the

disease, although not all studies agree (Jack et al., 2019; reviewed in Nebel et al., 2018).

Intriguingly, males are more likely to be diagnosed with aMCI compared to females (Jack et al.,

2019), whereas females progress faster from aMCI to AD (Lin et al., 2015). These findings are

similar to those in the current study as we found more males than females diagnosed with LMCI

but no sex difference in AD. Altogether, our study and previous research suggests that AD

females "catch up" to males and sex differences in tau-related pathology found in the current

study may be the underlying mechanism for this accelerated transition.

4.3 Sex differences in hippocampal volume depended on correction method

We found that the presence of APOEε4 alleles and AD diagnosis were associated with

reduced corrected hippocampal volume (both methods of correction) consistent with previous

literature (Buckner, 2004; Ewers et al., 2012; Jack et al., 2000; Li et al., 2016; Petersen et al.,

2000). Curiously, depending on the correction method, females had larger or smaller

hippocampal volume compared to males. Females had smaller corrected hippocampal volume

using the residuals of the linear regression between hippocampal volume and total intracranial

volume (regression method) but larger ratio of hippocampal/intracranial volume compared to

males. Similar findings have been shown before as sex differences depend on whether

hippocampal volume is corrected for by intracranial volume or total brain volume, and the

method of correction (Tan et al., 2016). In their meta-analysis, Tan et al. (2016) conclude that

sex differences in hippocampal volume are modest and highly depends on whether or not a

correction was applied and the method of correction which is supported by our findings. These

results have important implications for understanding sex differences in diseases that influence

the integrity of the hippocampus as they lead to very different conclusions regarding

hippocampal plasticity.

4.4 Limitations

The ADNI data are not representative of the population as it is mostly composed of white

and highly educated individuals. As ethnicity (Mayeda et al., 2016; Steenland et al., 2016) and

education (Sharp and Gatz, 2011) can affect incidence, prevalence and age of AD onset, our

conclusions may not apply to more ethnically and socially diverse populations. In this cohort, we

did not detect significant interactions between sex, APOE genotype, and diagnosis for any of the

endpoints analysed. Future research with large cohorts is required to further test how sex, APOE

genotype, and diagnosis interact together as well as how other life history characteristics such as

parity may play a role.

6. Conclusion

Levels of CSF tau and p-tau were disproportionately affected by APOE genotype in

females compared to males, however males had a higher reduction in CSF Aβ levels with APOE

genotype compared to females. Our results support the idea that there are sex differences in the

manifestation and pathology of AD with APOE genotype. Interestingly, although in this cohort

female APOEε4 carriers had elevated tau pathology, females (regardless of APOE genotype) had

higher memory scores compared to males in CN and aMCI groups. Therefore, it is possible that

females may have a reserve that protects the brain from damage to delay cognitive decline or

delay diagnosis but as the disease progresses the advantage in memory is reduced and females

show a faster trajectory of cognitive decline.

Acknowledgments

Data collection and sharing for this project was funded by the Alzheimer's Disease

Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD

ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the

National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering,

and through generous contributions from the following: AbbVie, Alzheimer's Association;

Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-

Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli

Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company

Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy

Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development

LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx

Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal

Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian

Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private

sector contributions are facilitated by the Foundation for the National Institutes of Health

(www.fnih.org). The grantee organization is the Northern California Institute for Research and

Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the

University of Southern California. ADNI data are disseminated by the Laboratory for Neuro

Imaging at the University of Southern California. Funding for this study was provided by a

Canadian Institutes of Health Research (CHIR) grant to LAMG (PJT-148662). PDG is funded by

the Alzheimer's Association of the USA and Brain Canada with the financial support of Health

Canada through the Brain Canada Research Fund (AARF-17-529705). The views expressed

herein do not necessarily represent the views of the Minister of Health or the Government of

Canada.

References

Altmann, A., Tian, L., Henderson, V.W., Greicius, M.D., 2014. Sex modifies the APOE-related risk of developing Alzheimer disease. Annals of Neurology 75, 563–573. https://doi.org/10.1002/ana.24135

Alzheimer's Association, 2017. 2017 Alzheimer's disease facts and figures. Alzheimer's & Dementia 13, 325–373. https://doi.org/10.1016/j.jalz.2017.02.001

Ardekani, B.A., Convit, A., Bachman, A.H., 2016. Analysis of the MIRIAD Data Shows Sex Differences in Hippocampal Atrophy Progression. J. Alzheimers Dis. 50, 847–857. https://doi.org/10.3233/JAD-150780

Asperholm, M., Högman, N., Rafi, J., Herlitz, A., 2019. What did you do yesterday? A meta-analysis of sex differences in episodic memory. Psychol Bull 145, 785–821. https://doi.org/10.1037/bul0000197

Benjamini, Y., Hochberg, Y., 1995. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. Series B (Methodological) 57, 289–300.

Blennow, K., Dubois, B., Fagan, A.M., Lewczuk, P., de Leon, M.J., Hampel, H., 2015. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimer's & Dementia 11, 58–69. https://doi.org/10.1016/j.jalz.2014.02.004

Buckley, R.F., Mormino, E.C., Amariglio, R.E., Properzi, M.J., Rabin, J.S., Lim, Y.Y., Papp, K.V., Jacobs, H.I.L., Burnham, S., Hanseeuw, B.J., Doré, V., Dobson, A., Masters, C.L., Waller, M., Rowe, C.C., Maruff, P., Donohue, M.C., Rentz, D.M., Kirn, D., Hedden, T., Chhatwal, J., Schultz, A.P., Johnson, K.A., Villemagne, V.L., Sperling, R.A., 2018. Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. Alzheimer's & Dementia 14, 1193–1203. https://doi.org/10.1016/j.jalz.2018.04.010

Buckley, R.F., Mormino, E.C., Chhatwal, J., Schultz, A.P., Rabin, J.S., Rentz, D.M., Acar, D., Properzi, M.J., Dumurgier, J., Jacobs, H., Gomez-Isla, T., Johnson, K.A., Sperling, R.A., Hanseeuw, B.J., 2019a. Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. Neurobiology of Aging 78, 178–185. https://doi.org/10.1016/j.neurobiolaging.2019.02.019

Buckley, R.F., Mormino, E.C., Rabin, J.S., Hohman, T.J., Landau, S., Hanseeuw, B.J., Jacobs, H.I.L., Papp, K.V., Amariglio, R.E., Properzi, M.J., Schultz, A.P., Kirn, D., Scott, M.R., Hedden, T., Farrell, M., Price, J., Chhatwal, J., Rentz, D.M., Villemagne, V.L., Johnson, K.A., Sperling, R.A., 2019b. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by

469   Positron Emission Tomography in Clinically Normal Older Adults. JAMA Neurol 76, 542–551.
470   https://doi.org/10.1001/jamaneurol.2018.4693

471 Buckner, R.L., 2004. Memory and Executive Function in Aging and AD: Multiple Factors that Cause
472   Decline and Reserve Factors that Compensate. Neuron 44, 195–208.
473   https://doi.org/10.1016/j.neuron.2004.09.006

474 Cavedo, E., Chiesa, P.A., Houot, M., Ferretti, M.T., Grothe, M.J., Teipel, S.J., Lista, S., Habert, M.-O.,
475   Potier, M.-C., Dubois, B., Hampel, H., Bakardjian, H., Benali, H., Bertin, H., Bonheur, J.,
476   Boukadida, L., Boukerrou, N., Cavedo, E., Chiesa, P., Colliot, O., Dubois, B., Dubois, M.,
477   Epelbaum, S., Gagliardi, G., Genthon, R., Habert, M.-O., Hampel, H., Houot, M., Kas, A., Lamari,
478   F., Levy, M., Lista, S., Metzinger, C., Mochel, F., Nyasse, F., Poisson, C., Potier, M.-C., Revillon, M.,
479   Santos, A., Andrade, K.S., Sole, M., Surtee, M., de Schotten, M.T., Vergallo, A., Younsi, N.,
480   Aguilar, L.F., Babiloni, C., Baldacci, F., Benda, N., Black, K.L., Bokde, A.L.W., Bonuccelli, U., Broich,
481   K., Bun, R.S., Cacciola, F., Castrillo, J., Cavedo, E., Ceravolo, R., Chiesa, P.A., Colliot, O., Coman,
482   C.-M., Corvol, J.-C., Cuello, A.C., Cummings, J.L., Depypere, H., Dubois, B., Duggento, A.,
483   Durrleman, S., Escott-Price, V., Federoff, H., Ferretti, M.T., Fiandaca, M., Frank, R.A., Garaci, F.,
484   Genthon, R., George, N., Giorgi, F.S., Graziani, M., Haberkamp, M., Habert, M.-O., Hampel, H.,
485   Herholz, K., Karran, E., Kim, S.H., Koronyo, Y., Koronyo-Hamaoui, M., Lamari, F., Langevin, T.,
486   Lehéricy, S., Lista, S., Lorenceau, J., Mapstone, M., Neri, C., Nisticò, R., Nyasse-Messene, F.,
487   O'bryant, S.E., Perry, G., Ritchie, C., Rojkova, K., Rossi, S., Saidi, A., Santarnecchi, E., Schneider,
488   L.S., Sporns, O., Toschi, N., Verdooner, S.R., Vergallo, A., Villain, N., Welikovitch, L.A., Woodcock,
489   J., Younesi, E., 2018. Sex differences in functional and molecular neuroimaging biomarkers of
490   Alzheimer's disease in cognitively normal older adults with subjective memory complaints.
491   Alzheimer's & Dementia 14, 1204–1215. https://doi.org/10.1016/j.jalz.2018.05.014

492 Crane, P.K., Carle, A., Gibbons, L.E., Insel, P., Mackin, R.S., Gross, A., Jones, R.N., Mukherjee, S., Curtis,
493   S.M., Harvey, D., Weiner, M., Mungas, D., Alzheimer's Disease Neuroimaging Initiative, 2012.
494   Development and assessment of a composite score for memory in the Alzheimer's Disease
495   Neuroimaging Initiative (ADNI). Brain Imaging Behav 6, 502–516.
496   https://doi.org/10.1007/s11682-012-9186-z

497 Damoiseaux, J.S., Seeley, W.W., Zhou, J., Shirer, W.R., Coppola, G., Karydas, A., Rosen, H.J., Miller, B.L.,
498   Kramer, J.H., Greicius, M.D., Alzheimer's Disease Neuroimaging Initiative, 2012. Gender
499   modulates the APOE ε4 effect in healthy older adults: convergent evidence from functional
500   brain connectivity and spinal fluid tau levels. J. Neurosci. 32, 8254–8262.
501   https://doi.org/10.1523/JNEUROSCI.0305-12.2012

502 Ewers, M., Walsh, C., Trojanowski, J.Q., Shaw, L.M., Petersen, R.C., Jack, C.R., Feldman, H.H., Bokde,
503   A.L.W., Alexander, G.E., Scheltens, P., Vellas, B., Dubois, B., Weiner, M., Hampel, H., 2012.
504   Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based
505   upon biomarkers and neuropsychological test performance. Neurobiology of Aging 33, 1203-
506   1214.e2. https://doi.org/10.1016/j.neurobiolaging.2010.10.019

507 Ferretti, M.T., Iulita, M.F., Cavedo, E., Chiesa, P.A., Schumacher Dimech, A., Santuccione Chadha, A.,
508   Baracchi, F., Girouard, H., Misoch, S., Giacobini, E., Depypere, H., Hampel, H., 2018. Sex
509   differences in Alzheimer disease — the gateway to precision medicine. Nature Reviews
510   Neurology 14, 457–469. https://doi.org/10.1038/s41582-018-0032-9

511 Gaillard, A., Fehring, D.J., Rossell, S.L., 2020. A systematic review and meta-analysis of behavioural sex
512   differences in executive control. European Journal of Neuroscience.
513   https://doi.org/10.1111/ejn.14946

514 Gibbons, L.E., Carle, A.C., Mackin, R.S., Harvey, D., Mukherjee, S., Insel, P., Curtis, S.M., Mungas, D.,
515   Crane, P.K., Alzheimer's Disease Neuroimaging Initiative, 2012. A composite score for executive
516   functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with

baseline mild cognitive impairment. Brain Imaging Behav 6, 517–527.
https://doi.org/10.1007/s11682-012-9176-1

Hohman, T.J., Dumitrescu, L., Barnes, L.L., Thambisetty, M., Beecham, G., Kunkle, B., Gifford, K.A., Bush, W.S., Chibnik, L.B., Mukherjee, S., Jager, P.L.D., Kukull, W., Crane, P.K., Resnick, S.M., Keene, C.D., Montine, T.J., Schellenberg, G.D., Haines, J.L., Zetterberg, H., Blennow, K., Larson, E.B., Johnson, S.C., Albert, M., Bennett, D.A., Schneider, J.A., Jefferson, A.L., 2018. Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. JAMA Neurol 75, 989–998. https://doi.org/10.1001/jamaneurol.2018.0821

Holland, D., Desikan, R.S., Dale, A.M., McEvoy, L.K., Alzheimer's Disease Neuroimaging Initiative, 2013. Higher rates of decline for women and apolipoprotein E epsilon4 carriers. AJNR Am J Neuroradiol 34, 2287–2293. https://doi.org/10.3174/ajnr.A3601

Hua, X., Hibar, D.P., Lee, S., Toga, A.W., Jack, C.R., Weiner, M.W., Thompson, P.M., 2010. Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans. Neurobiology of Aging 31, 1463–1480. https://doi.org/10.1016/j.neurobiolaging.2010.04.033

Irvine, K., Laws, K.R., Gale, T.M., Kondel, T.K., 2012. Greater cognitive deterioration in women than men with Alzheimer's disease: a meta analysis. J Clin Exp Neuropsychol 34, 989–998. https://doi.org/10.1080/13803395.2012.712676

Jack, C.R., Dickson, D.W., Parisi, J.E., Xu, Y.C., Cha, R.H., O'Brien, P.C., Edland, S.D., Smith, G.E., Boeve, B.F., Tangalos, E.G., Kokmen, E., Petersen, R.C., 2002. Antemortem MRI Findings Correlate with Hippocampal Neuropathology in Typical Aging and Dementia. Neurology 58, 750–757.

Jack, C.R., Knopman, D.S., Weigand, S.D., Wiste, H.J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J.L., Senjem, M.L., Ivnik, R.J., Roberts, R.O., Rocca, W.A., Boeve, B.F., Petersen, R.C., 2012. An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease. Annals of Neurology 71, 765–775. https://doi.org/10.1002/ana.22628

Jack, C.R., Petersen, R.C., Xu, Y., O'Brien, P.C., Smith, G.E., Ivnik, R.J., Boeve, B.F., Tangalos, E.G., Kokmen, E., 2000. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 55, 484–489. https://doi.org/10.1212/wnl.55.4.484

Jack, C.R., Therneau, T.M., Weigand, S.D., Wiste, H.J., Knopman, D.S., Vemuri, P., Lowe, V.J., Mielke, M.M., Roberts, R.O., Machulda, M.M., Graff-Radford, J., Jones, D.T., Schwarz, C.G., Gunter, J.L., Senjem, M.L., Rocca, W.A., Petersen, R.C., 2019. Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging–Alzheimer's Association Research Framework. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2019.1971

Jack, C.R., Wiste, H.J., Weigand, S.D., Knopman, D.S., Vemuri, P., Mielke, M.M., Lowe, V., Senjem, M.L., Gunter, J.L., Machulda, M.M., Gregg, B.E., Pankratz, V.S., Rocca, W.A., Petersen, R.C., 2015. Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span. JAMA Neurol 72, 511–519. https://doi.org/10.1001/jamaneurol.2014.4821

Kidron, D., Black, S.E., Stanchev, P., Buck, B., Szalai, J.P., Parker, J., Szekely, C., Bronskill, M.J., 1997. Quantitative MR volumetry in Alzheimer's disease: Topographic markers and the effects of sex and education. Neurology 49, 1504–1512. https://doi.org/10.1212/WNL.49.6.1504

Li, B., Shi, J., Gutman, B.A., Baxter, L.C., Thompson, P.M., Caselli, R.J., Wang, Y., 2016. Influence of APOE Genotype on Hippocampal Atrophy over Time - An N=1925 Surface-Based ADNI Study. PLoS One 11. https://doi.org/10.1371/journal.pone.0152901

Lin, K.A., Choudhury, K.R., Rathakrishnan, B.G., Marks, D.M., Petrella, J.R., Doraiswamy, P.M., 2015. Marked gender differences in progression of mild cognitive impairment over 8 years. Alzheimer's & Dementia: Translational Research & Clinical Interventions 1, 103–110. https://doi.org/10.1016/j.trci.2015.07.001

Liu, M., Paranjpe, M.D., Zhou, X., Duy, P.Q., Goyal, M.S., Benzinger, T.L.S., Lu, J., Wang, R., Zhou, Y.,
2019. Sex modulates the ApoE ε4 effect on brain tau deposition measured by 18F-AV-1451 PET
in individuals with mild cognitive impairment. Theranostics 9, 4959–4970.
https://doi.org/10.7150/thno.35366
Lotze, M., Domin, M., Gerlach, F.H., Gaser, C., Lueders, E., Schmidt, C.O., Neumann, N., 2019. Novel
findings from 2,838 Adult Brains on Sex Differences in Gray Matter Brain Volume. Scientific
Reports 9, 1671. https://doi.org/10.1038/s41598-018-38239-2
Maass, A., Landau, S., Baker, S.L., Horng, A., Lockhart, S.N., La Joie, R., Rabinovici, G.D., Jagust, W.J.,
2017. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.
NeuroImage 157, 448–463. https://doi.org/10.1016/j.neuroimage.2017.05.058
Mayeda, E.R., Glymour, M.M., Quesenberry, C.P., Whitmer, R.A., 2016. Inequalities in dementia
incidence between six racial and ethnic groups over 14 years. Alzheimer's & Dementia 12, 216–
224. https://doi.org/10.1016/j.jalz.2015.12.007
Mormino, E.C., Betensky, R.A., Hedden, T., Schultz, A.P., Amariglio, R.E., Rentz, D.M., Johnson, K.A.,
Sperling, R.A., 2014. Synergistic Effect of β-Amyloid and Neurodegeneration on Cognitive
Decline in Clinically Normal Individuals. JAMA Neurol 71, 1379–1385.
https://doi.org/10.1001/jamaneurol.2014.2031
Nebel, R.A., Aggarwal, N.T., Barnes, L.L., Gallagher, A., Goldstein, J.M., Kantarci, K., Mallampalli, M.P.,
Mormino, E.C., Scott, L., Yu, W.H., Maki, P.M., Mielke, M.M., 2018. Understanding the impact of
sex and gender in Alzheimer's disease: A call to action. Alzheimer's & Dementia 14, 1171–1183.
https://doi.org/10.1016/j.jalz.2018.04.008
Neu, S.C., Pa, J., Kukull, W., Beekly, D., Kuzma, A., Gangadharan, P., Wang, L.-S., Romero, K., Arneric, S.P.,
Redolfi, A., Orlandi, D., Frisoni, G.B., Au, R., Devine, S., Auerbach, S., Espinosa, A., Boada, M.,
Ruiz, A., Johnson, S.C., Koscik, R., Wang, J.-J., Hsu, W.-C., Chen, Y.-L., Toga, A.W., 2017.
Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis. JAMA
Neurol. https://doi.org/10.1001/jamaneurol.2017.2188
Petersen, R.C., Jack, C.R., Xu, Y.C., Waring, S.C., O'Brien, P.C., Smith, G.E., Ivnik, R.J., Tangalos, E.G.,
Boeve, B.F., Kokmen, E., 2000. Memory and MRI-based hippocampal volumes in aging and AD.
Neurology 54, 581–587. https://doi.org/10.1212/wnl.54.3.581
R Core Team, 2018. A language and environment for statistical computing. R Foundation for Statistical
Computing, Vienna, Austria. URL https://www.R-project.org/.
Riedel, B.C., Thompson, P.M., Brinton, R.D., 2016. Age, APOE and sex: Triad of risk of Alzheimer's
disease. The Journal of Steroid Biochemistry and Molecular Biology 160, 134–147.
https://doi.org/10.1016/j.jsbmb.2016.03.012
Sampedro, F., Vilaplana, E., de Leon, M.J., Alcolea, D., Pegueroles, J., Montal, V., Carmona-Iragui, M.,
Sala, I., Sánchez-Saudinos, M.-B., Antón-Aguirre, S., Morenas-Rodríguez, E., Camacho, V., Falcón,
C., Pavía, J., Ros, D., Clarimón, J., Blesa, R., Lleó, A., Fortea, J., Alzheimer's Disease Neuroimaging
Initiative, 2015. APOE-by-sex interactions on brain structure and metabolism in healthy elderly
controls. Oncotarget 6, 26663–26674. https://doi.org/10.18632/oncotarget.5185
Sharp, E.S., Gatz, M., 2011. The Relationship between Education and Dementia An Updated Systematic
Review. Alzheimer Dis Assoc Disord 25, 289–304.
https://doi.org/10.1097/WAD.0b013e318211c83c
Sohn, D., Shpanskaya, K., Lucas, J.E., Petrella, J.R., Saykin, A.J., Tanzi, R.E., Samatova, N.F., Doraiswamy,
P.M., 2018. Sex Differences in Cognitive Decline in Subjects with High Likelihood of Mild
Cognitive Impairment due to Alzheimer's disease. Scientific Reports 8, 7490.
https://doi.org/10.1038/s41598-018-25377-w

Steenland, K., Goldstein, F.C., Levey, A., Wharton, W., 2016. A Meta-Analysis of Alzheimer's Disease
Incidence and Prevalence Comparing African-Americans and Caucasians. J. Alzheimers Dis. 50,
71–76. https://doi.org/10.3233/JAD-150778
Sundermann, E.E., Biegon, A., Rubin, L.H., Lipton, R.B., Landau, S., Maki, P.M., Alzheimer's Disease
Neuroimaging Initiative, 2017. Does the Female Advantage in Verbal Memory Contribute to
Underestimating Alzheimer's Disease Pathology in Women versus Men? J. Alzheimers Dis. 56,
947–957. https://doi.org/10.3233/JAD-160716
Sundermann, E.E., Biegon, A., Rubin, L.H., Lipton, R.B., Mowrey, W., Landau, S., Maki, P.M., 2016. Better
verbal memory in women than men in MCI despite similar levels of hippocampal atrophy.
Neurology 86, 1368–1376. https://doi.org/10.1212/WNL.0000000000002570
Sundermann, E.E., Tran, M., Maki, P.M., Bondi, M.W., 2018. Sex differences in the association between
apolipoprotein E ε4 allele and Alzheimer's disease markers. Alzheimer's & Dementia: Diagnosis,
Assessment & Disease Monitoring 10, 438–447. https://doi.org/10.1016/j.dadm.2018.06.004
Tan, A., Ma, W., Vira, A., Marwha, D., Eliot, L., 2016. The human hippocampus is not sexually-dimorphic:
Meta-analysis of structural MRI volumes. NeuroImage 124, 350–366.
https://doi.org/10.1016/j.neuroimage.2015.08.050
Wang, X., Zhou, W., Ye, T., Lin, X., Zhang, J., Initiative, for A.D.N., 2019. Sex Difference in the Association
of APOE4 with Memory Decline in Mild Cognitive Impairment. Journal of Alzheimer's Disease 69,
1161–1169. https://doi.org/10.3233/JAD-181234
Yagi, S., Galea, L.A.M., 2019. Sex differences in hippocampal cognition and neurogenesis.
Neuropsychopharmacology 44, 200–213. https://doi.org/10.1038/s41386-018-0208-4
631

Figure captions

Figure 1. A. Levels of CSF AD biomarkers tau (pg/ml; A), p-tau (pg/ml; B), and amyloid beta

(pg/ml; C) in ADNI participants by sex and APOE genotype (absence or presence of APOEε4

alleles).

Figure 2. Memory scores in ADNI participants by sex and diagnosis (CN, EMCI, LMCI, AD).

CN, cognitively normal; EMCI, early mild cognitive impairment; LMCI, late mild cognitive

impairment; AD, Alzheimer's disease.

Table 1. Demographic and clinical information for all participants and subdivided by sex. We collapsed APOE genotype into two groups: (1) participants carrying any ε4 alleles (homozygous ε4/ε4 and heterozygous ε4/-) and (2) participants with no ε4 risk alleles (-/-).Biomarkers for AD are from cerebrospinal fluid. Volume of the hippocampus was corrected using a regression method or using a ratio with intracranial volume (see methods for more details). CN, cognitively normal; EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment; AD, Alzheimer's disease.

		Sex		
	Total	**Female**	**Male**	**P-value**
	No. 1,460	**No. 630**	**No. 830**	
Age				
Mean (SD)	74.13 (±7.25)	73.15 (±7.28)	74.87 (±7.14)	< 0.0001
Education (years)				
Mean (SD)	15.83 (±2.88)	15.15 (±2.79)	16.34 (±2.85)	< 0.0001
Ethnicity				
White	1,352 (92.60%)	573 (90.95%)	779 (93.86%)	0.043
Not white	108 (7.40%)	57 (9.05%)	51 (6.14%)	
Baseline diagnosis				
CN	341 (23.4%)	168 (26.7%)	173 (20.8%)	0.013
EMCI	257 (17.6%)	108 (17.1%)	149 (18.0%)	
LMCI	533 (36.5%)	205 (32.5%)	328 (39.5%)	
AD	329 (22.5%)	149 (23.7%)	180 (21.7%)	
APOEε4 allele number				
0	702 (48.08%)	300 (47.62%)	402 (48.43%)	0.87
1 or 2	744 (50.96%)	322 (51.11%)	422 (50.84%)	
Missing	14 (0.96%)	8 (1.27%)	6 (0.72%)	
Amyloid Beta				
Mean (SD)	830.97 (±358.04)	856.41 (±346.87)	812.44 (±365.16)	0.016
Missing	513 (35.14%)	231 (36.67%)	282 (33.98%)	
Tau				
Mean (SD)	294.38 (±137.27)	314.56 (±152.70)	279.70 (±122.91)	0.002
Missing	513 (35.14%)	231 (36.67%)	282 (33.98%)	
PTau				
Mean (SD)	28.89 (±15.31)	30.87 (±16.95)	27.44 (±13.83)	0.007
Missing	513 (35.14%)	231 (36.67%)	282 (33.98%)	
Volume of hippocampus (uncorrected, mm^3)				
Mean (SD)	6659.47 (±1176.42)	6446.71 (±1169.97)	6822.86 (±1155.87)	< 0.0001
Missing	226 (15.48%)	94 (14.92%)	132 (15.90%)	
Volume of hippocampus (regression corrected)				
Mean (SD)	6662.60 (±1137.98)	6647.21 (±1134.41)	6674.43 (±1141.38)	0.83
Missing	226 (15.48%)	94 (14.92%)	132 (15.90%)	
Volume of hippocampus/intracranial volume				
Mean (SD)	0.00436 (±0.00080)	0.00454 (±0.00082)	0.00423 (±0.00076)	< 0.0001
Missing	226 (15.48%)	94 (14.92%)	132 (15.90%)	
Executive Function (ADNI_EF)				
Mean (SD)	0.02 (±0.96)	0.06 (±0.97)	-0.00 (±0.95)	0.20
Missing	311 (21.30%)	145 (23.02%)	166 (20.00%)	
Memory (ADNI_MEM)				
Mean (SD)	0.10 (±0.87)	0.21 (±0.94)	0.02 (±0.80)	0.0006
Missing	310 (21.23%)	145 (23.02%)	165 (19.88%)	

P-values are from Wilcoxon rank sum tests for continuous variables and Fisher's exact tests for categorical variables. Missing refers to number of individuals and the percent of the total cohort that had missing data for that variable

Table 2. Linear regression results for models with sex, baseline diagnosis (CN, cognitively normal; EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment; AD, Alzheimer's disease), and APOE4 genotype (non-carriers or carriers of APOEε4 alleles). P-values are for overall tests and are FDR-adjusted. The three-way interactions were not significant for any of the endpoints.

Predictors	CSF tau Estimates (CI)	adjusted p	CSF ptau Estimates (CI)	adjusted p	CSF amyloid beta Estimates (CI)	adjusted p	ADNI Memory z-scores Estimates (CI)	adjusted p	Hippocampus volume (regression method) Estimates (CI)	adjusted p	Hippocampus volume (ratio method) Estimates (CI)	adjusted p	ADNI executive function z-scores Estimates (CI)	adjusted p
(Intercept)	122.071 (21.390 – 222.751)		12.353 (1.073 – 23.634)		1345.533 (1090.268 – 1600.798)		1.233 (0.830 – 1.636)		11678.924 (11048.176 – 12309.672)		0.007804 (0.007354 – 0.008253)		1.163 (0.620 – 1.706)	
Age (years)	1.877 (0.785 – 2.968)		0.171 (0.049 – 0.293)		-3.435 (-6.205 – -0.665)		-0.009 (-0.014 – -0.005)		-56.765 (-63.754 – -49.776)		-0.000035 (-0.000040 – -0.000030)		-0.018 (-0.024 – -0.012)	
Education (years)	-2.623 (-5.543 – 0.296)		-0.309 (-0.636 – 0.018)		-0.194 (-7.605 – 7.216)		0.039 (0.028 – 0.050)		-5.197 (-22.724 – 12.331)		-0.000012 (-0.000025 – -0.000001)		0.06 (0.045 – 0.075)	
Sex (ref = Female)	-12.488 (-36.012 – 11.035)		-0.898 (-3.533 – 1.738)		14.218 (-45.217 – 73.653)		-0.312 (-0.441 – -0.183)		160.824 (59.289 – 262.358)	**0.005**	-0.000209 (-0.000282 – -0.000137)	**<0.0001**	-0.12 (-0.209 – -0.030)	**0.013**
APOE genotype 1/2 ε4 alleles (ref = 0 alleles)	68.1 (27.535 – 108.666)		7.892 (3.347 – 12.437)		-181.294 (-244.764 – -117.823)		0.003 (-0.135 – 0.141)		-168.092 (-383.487 – 47.303)		-0.000098 (-0.000251 – 0.000056)		-0.019 (-0.108 – 0.071)	
Diagnosis (ref = CN)						**<0.0001**								**<0.0001**
EMCI	7.301 (-23.079 – 37.680)		1.097 (-2.307 – 4.501)		-47.41 (-107.884 – 13.063)		-0.368 (-0.548 – -0.189)		-418.899 (-613.299 – -224.499)		-0.000268 (-0.000406 – -0.000129)		-0.364 (-0.508 – -0.220)	
LMCI	57.532 (28.003 – 87.060)		6.579 (3.271 – 9.888)		-199.567 (-256.429 – -142.706)		-0.987 (-1.133 – -0.842)		-870.939 (-1042.393 – -699.486)		-0.000742 (-0.000742 – -0.000498)		-0.739 (-0.852 – -0.625)	
AD	138.893 (103.054 – 174.731)		15.066 (11.051 – 19.082)		-302.024 (-364.130 – -239.918)		-1.873 (-2.043 – -1.703)		-1335.151 (-1557.409 – -1112.893)		-0.000889 (-0.001048 – -0.000731)		-1.538 (-1.669 – -1.406)	
Sex and APOE genotype interaction		**0.005**		**0.006**		**0.051**								
Male:1/2 alleles	-48.757 (-80.588 – -16.925)		-5.296 (-8.863 – -1.730)		-81.141 (-161.739 – -0.544)									
Sex and Diagnosis interaction								**0.048**						
Male:EMCI							-0.039 (-0.247 – 0.170)							
Male:LMCI							0.154 (-0.011 – 0.319)							
Male:AD							0.196 (0.012 – 0.380)							
APOE genotype and Diagnosis interaction		**0.014**		**0.029**				**0.006**		**0.0007**		**0.0006**		
1/2 alleles:EMCI	47.661 (-1.441 – 96.763)		4.566 (-0.935 – 10.068)				-0.15 (-0.363 – 0.063)		271.861 (-38.411 – 582.133)		0.00023 (0.000009 – 0.000451)			
1/2 alleles:LMCI	39.03 (-7.355 – 85.416)		4.195 (-1.003 – 9.392)				-0.283 (-0.454 – -0.112)		-282.503 (-553.376 – -11.630)		-0.000166 (-0.000360 – 0.000027)			
1/2 alleles:AD	-21.574 (-72.727 – 29.579)		-2.323 (-8.054 – 3.409)				-0.034 (-0.234 – 0.165)		-303.523 (-615.962 – 8.916)		-0.000214 (-0.000436 – 0.000009)			
Observations	947		947		947		1145		1224		1224		1144	
R² / R²adjusted	0.227 / 0.218		0.220 / 0.211		0.264 / 0.258		0.621 / 0.616		0.431 / 0.427		0.415 / 0.410		0.411 / 0.408	

Table 3. Correlations between CSF levels of tau and amyloid beta, CSF tau and memory scores, and CSF amyloid beta and memory scores, depending by sex and APOE genotype (non carriers versus carriers of ε4 alleles)

Variables	APOE genotype	Correlation in females	p-value	Correlation in males	p-value
CSF tau and Aβ					
	Non carriers	-0.195 (-0.330 to - 0.053)	**0.008**	-0.262 (-0.372 to -0.145)	**< 0.0001**
	Carriers of APOEε4 alleles	-0.219 (-0.343 to -0.088)	**0.001**	-0.046 (-0.160 to 0.070)	0.44
CSF tau and memory z-scores					
	Non carriers	-0.397 (-0.532 to -0.244)	**< 0.0001**	-0.394 (-0.507 to -0.268)	**< 0.0001**
	Carriers of APOEε4 alleles	-0.242 (-0.387 to -0.086)	**0.003**	-0.232 (-0.355 to -0.100)	**0.0007**
CSF Aβ and memory z-scores					
	Non carriers	0.425 (0.275 to 0.555)	**< 0.0001**	0.305 (0.172 to 0.428)	**< 0.0001**
	Carriers of APOEε4 alleles	0.407 (0.265 to 0.533)	**< 0.0001**	0.413 (0.295 to 0.519)	**< 0.0001**

Figure 1

Figure 2